UK markets closed
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • FTSE 250

    22,324.19
    -210.91 (-0.94%)
     
  • AIM

    1,229.80
    -11.57 (-0.93%)
     
  • GBP/EUR

    1.1633
    -0.0056 (-0.48%)
     
  • GBP/USD

    1.3801
    -0.0123 (-0.88%)
     
  • BTC-GBP

    25,716.96
    -443.07 (-1.69%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.32 (-1.58%)
     
  • CRUDE OIL

    71.50
    -0.14 (-0.20%)
     
  • GOLD FUTURES

    1,763.90
    -5.10 (-0.29%)
     
  • NIKKEI 225

    28,964.08
    -54.22 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.67 (+0.85%)
     
  • DAX

    15,448.04
    -279.66 (-1.78%)
     
  • CAC 40

    6,569.16
    -97.10 (-1.46%)
     

Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued

·4-min read

- By GF Value

The stock of Syndax Pharmaceuticals (NAS:SNDX, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $15.47 per share and the market cap of $746.2 million, Syndax Pharmaceuticals stock appears to be significantly overvalued. GF Value for Syndax Pharmaceuticals is shown in the chart below.


Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued

Because Syndax Pharmaceuticals is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.

Link: These companies may deliever higher future returns at reduced risk.

Companies with poor financial strength offer investors a high risk of permanent capital loss. To avoid permanent capital loss, an investor must do their research and review a company's financial strength before deciding to purchase shares. Both the cash-to-debt ratio and interest coverage of a company are a great way to to understand its financial strength. Syndax Pharmaceuticals has a cash-to-debt ratio of 14.27, which which ranks in the middle range of the companies in Biotechnology industry. The overall financial strength of Syndax Pharmaceuticals is 5 out of 10, which indicates that the financial strength of Syndax Pharmaceuticals is fair. This is the debt and cash of Syndax Pharmaceuticals over the past years:

Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued

Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Syndax Pharmaceuticals has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $1.5 million and loss of $1.88 a share. Its operating margin is -4711.35%, which ranks worse than 86% of the companies in Biotechnology industry. Overall, the profitability of Syndax Pharmaceuticals is ranked 1 out of 10, which indicates poor profitability. This is the revenue and net income of Syndax Pharmaceuticals over the past years:

Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Syndax Pharmaceuticals is -28.2%, which ranks worse than 73% of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is 16.6%, which ranks in the middle range of the companies in Biotechnology industry.

Another method of determining the profitability of a company is to compare its return on invested capital to the weighted average cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. When the ROIC is higher than the WACC, it implies the company is creating value for shareholders. For the past 12 months, Syndax Pharmaceuticals's return on invested capital is -1079.96, and its cost of capital is 12.87. The historical ROIC vs WACC comparison of Syndax Pharmaceuticals is shown below:

Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued

To conclude, Syndax Pharmaceuticals (NAS:SNDX, 30-year Financials) stock appears to be significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Syndax Pharmaceuticals stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting